US 12161674
CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
granted A61KA61K31/255A61K31/395
Quick answer
US patent 12161674 (CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof) held by Vertex Pharmaceuticals Incorporated expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vertex Pharmaceuticals Incorporated
- Grant date
- Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/255, A61K31/395, A61K31/4535, A61K35/18